CVA Family Office LLC Cuts Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

CVA Family Office LLC lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 43.6% in the third quarter, HoldingsChannel reports. The institutional investor owned 155 shares of the medical research company’s stock after selling 120 shares during the quarter. CVA Family Office LLC’s holdings in IQVIA were worth $28,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. State Street Corp grew its position in shares of IQVIA by 3.8% during the second quarter. State Street Corp now owns 8,622,096 shares of the medical research company’s stock valued at $1,870,909,000 after purchasing an additional 315,751 shares in the last quarter. Alliancebernstein L.P. grew its position in shares of IQVIA by 20.1% during the third quarter. Alliancebernstein L.P. now owns 5,157,158 shares of the medical research company’s stock valued at $934,167,000 after purchasing an additional 862,222 shares in the last quarter. Bishop Rock Capital L.P. grew its position in shares of IQVIA by 14,549.4% during the second quarter. Bishop Rock Capital L.P. now owns 4,050,552 shares of the medical research company’s stock valued at $18,667,000 after purchasing an additional 4,022,902 shares in the last quarter. Amundi grew its position in IQVIA by 11.3% in the second quarter. Amundi now owns 2,078,718 shares of the medical research company’s stock worth $440,687,000 after acquiring an additional 211,026 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its position in IQVIA by 5.8% in the first quarter. Goldman Sachs Group Inc. now owns 1,739,693 shares of the medical research company’s stock worth $402,235,000 after acquiring an additional 95,860 shares in the last quarter. Hedge funds and other institutional investors own 86.20% of the company’s stock.

IQVIA Stock Performance

IQVIA stock opened at $190.89 on Friday. The company has a 50 day moving average price of $218.94 and a 200-day moving average price of $208.72. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.89 and a current ratio of 0.89. IQVIA Holdings Inc. has a fifty-two week low of $165.75 and a fifty-two week high of $254.94. The company has a market capitalization of $35.53 billion, a PE ratio of 33.43, a P/E/G ratio of 1.97 and a beta of 1.40.

IQVIA (NYSE:IQV – Get Rating) last posted its quarterly earnings results on Friday, February 10th. The medical research company reported $2.78 earnings per share for the quarter, beating the consensus estimate of $2.76 by $0.02. IQVIA had a net margin of 7.57% and a return on equity of 31.88%. The firm had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.71 billion. During the same quarter in the previous year, the firm posted $2.42 earnings per share. The company’s revenue was up 2.8% on a year-over-year basis. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 9.46 earnings per share for the current year.

Insider Activity at IQVIA

In related news, insider Kevin C. Knightly sold 4,446 shares of IQVIA stock in a transaction that occurred on Thursday, February 16th. The shares were sold at an average price of $225.61, for a total transaction of $1,003,062.06. Following the transaction, the insider now directly owns 1,973 shares of the company’s stock, valued at $445,128.53. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, insider Kevin C. Knightly sold 4,446 shares of IQVIA stock in a transaction that occurred on Thursday, February 16th. The shares were sold at an average price of $225.61, for a total transaction of $1,003,062.06. Following the transaction, the insider now directly owns 1,973 shares of the company’s stock, valued at $445,128.53. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Eric Sherbet sold 1,000 shares of IQVIA stock in a transaction that occurred on Tuesday, February 14th. The shares were sold at an average price of $230.00, for a total transaction of $230,000.00. Following the transaction, the insider now directly owns 17,053 shares in the company, valued at $3,922,190. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Credit Suisse Group reiterated an “outperform” rating and issued a $265.00 price target on shares of IQVIA in a research report on Monday, February 13th. StockNews.com assumed coverage on IQVIA in a research report on Thursday. They issued a “hold” rating for the company. Truist Financial began coverage on IQVIA in a research report on Friday. They issued a “buy” rating and a $265.00 price target for the company. Cowen began coverage on shares of IQVIA in a research note on Tuesday, December 6th. They issued an “outperform” rating and a $251.00 price objective for the company. Finally, Cowen began coverage on shares of IQVIA in a research note on Tuesday, December 6th. They issued an “outperform” rating for the company. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $256.81.

IQVIA Profile

(Get Rating)

IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm’s life science clients.